Patients with SARS-CoV2 infection and cardiovascular comorbidities are exposed to higher risk of developing the severe form of the disease, increased risk of death, and need for intensive care, most probably due to cytokine storm and fulminant myocarditis. During the COVID-19 pandemic, clinicians have shown a great interest in using hydroxychloroquine (HCQ) or its predecessor chloroquine (CQ) in order to improve virucidal effectiveness against SARSCoV-2, but the concern of increased risk of QT prolongation and life-threatening conditions, such as torsades de pointes, counterbalance this tendency. The cause of the myocardial electrical disturbance in COVID patients is difficult to pinpoint as it may be related to the cardiac involvement of the disease as well as to the treatment with HCQ. Thus, if HCQ is proven to be efficient in COVID-19 patients, there are studies suggesting that the cardiac conductance anomalies can be avoided by using other therapeutic strategies. The aim of the present manuscript is to provide a short summary on the use of HCQ in patients with COVID-19.